Nothing Special   »   [go: up one dir, main page]

HRP20100113T1 - Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja - Google Patents

Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja Download PDF

Info

Publication number
HRP20100113T1
HRP20100113T1 HR20100113T HRP20100113T HRP20100113T1 HR P20100113 T1 HRP20100113 T1 HR P20100113T1 HR 20100113 T HR20100113 T HR 20100113T HR P20100113 T HRP20100113 T HR P20100113T HR P20100113 T1 HRP20100113 T1 HR P20100113T1
Authority
HR
Croatia
Prior art keywords
opioid receptor
receptor antagonist
treatment
containing compositions
kappa opioid
Prior art date
Application number
HR20100113T
Other languages
English (en)
Inventor
Lars Hermann Holger
Original Assignee
Emodys Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006015733A external-priority patent/DE102006015733A1/de
Priority claimed from DE102006016991A external-priority patent/DE102006016991A1/de
Application filed by Emodys Gmbh filed Critical Emodys Gmbh
Publication of HRP20100113T1 publication Critical patent/HRP20100113T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Upotreba pripravka koji sadrži antagonist kapa-opioidnog receptora sljedeće formule, naznačena time što je navedeni antagonist namijenjen proizvodnji lijeka za liječenje emocionalno nestabilne ličnosti (F60.3 u ICD-10) kod ljudi: ili njegove farmaceutski prihvatljive soli, estere, etere i/ili hidrate. Patent sadrži još 2 patentna zahtjeva.

Claims (3)

1. Upotreba pripravka koji sadrži antagonist kapa-opioidnog receptora sljedeće formule, naznačena time što je navedeni antagonist namijenjen proizvodnji lijeka za liječenje emocionalno nestabilne ličnosti (F60.3 u ICD-10) kod ljudi: [image] ili njegove farmaceutski prihvatljive soli, estere, etere i/ili hidrate.
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što pripravak također sadrži antagonist opioidnih receptora.
3. Upotreba u skladu s prethodnim patentnim zahtjevom, naznačena time što antagonist opioidnih receptora je nalokson.
HR20100113T 2006-04-04 2010-03-02 Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja HRP20100113T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006015733A DE102006015733A1 (de) 2006-04-04 2006-04-04 Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit
DE102006016991A DE102006016991A1 (de) 2006-04-11 2006-04-11 Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen
PCT/EP2007/053248 WO2007115975A2 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Publications (1)

Publication Number Publication Date
HRP20100113T1 true HRP20100113T1 (hr) 2010-04-30

Family

ID=38110094

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100113T HRP20100113T1 (hr) 2006-04-04 2010-03-02 Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja

Country Status (17)

Country Link
US (1) US8063059B2 (hr)
EP (1) EP2001456B1 (hr)
JP (1) JP5128578B2 (hr)
AT (1) ATE450256T1 (hr)
AU (1) AU2007236003B2 (hr)
CA (1) CA2646899C (hr)
CY (1) CY1109862T1 (hr)
DE (1) DE502007002185D1 (hr)
DK (1) DK2001456T3 (hr)
EA (1) EA014820B1 (hr)
ES (1) ES2337622T3 (hr)
HR (1) HRP20100113T1 (hr)
PL (1) PL2001456T3 (hr)
PT (1) PT2001456E (hr)
RS (1) RS51211B (hr)
SI (1) SI2001456T1 (hr)
WO (1) WO2007115975A2 (hr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422369B (zh) 2008-01-22 2014-01-11 Lilly Co Eli κ選擇性類鴉片受體拮抗劑
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
ES2694352T3 (es) * 2013-12-20 2018-12-20 H. Lundbeck A/S Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas
ES2658766T3 (es) 2014-04-28 2018-03-12 Orphomed, Inc. Dímero de buprenorfina y uso en el tratamiento de trastornos gastrointestinales
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US20220370409A1 (en) 2021-05-04 2022-11-24 Janssen Pharmaceuticals, Inc. Compositions And Methods For The Treatment Of Depression
TW202345796A (zh) 2022-03-07 2023-12-01 美商健生醫藥公司 阿替卡普蘭（ａｔｉｃａｐｒａｎｔ）之形式

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
WO1999045906A1 (en) 1998-03-09 1999-09-16 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
EP1365756A2 (en) 2000-08-15 2003-12-03 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
US20020045572A1 (en) 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
EP1353665A4 (en) 2000-12-21 2004-05-06 Mclean Hospital Corp TREATMENT OF DEPRESSION
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
CN100537564C (zh) * 2003-04-04 2009-09-09 麦克公司 代谢型谷氨酸受体-5的二芳基取代三唑调节剂
BRPI0508254A (pt) * 2004-03-02 2007-07-24 Pharmacia Corp métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
BRPI0510406A (pt) * 2004-05-26 2007-12-26 Inotek Pharmaceuticals Corp derivados de purina como agonistas do receptor de adenosina a1 e métodos de uso destes
DE602004017514D1 (de) 2004-06-02 2008-12-11 Galephar M F Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon

Also Published As

Publication number Publication date
CA2646899C (en) 2014-05-06
DK2001456T3 (da) 2010-04-12
ATE450256T1 (de) 2009-12-15
JP2009532434A (ja) 2009-09-10
US8063059B2 (en) 2011-11-22
CY1109862T1 (el) 2014-09-10
US20090181999A1 (en) 2009-07-16
EP2001456A2 (de) 2008-12-17
EA014820B1 (ru) 2011-02-28
SI2001456T1 (sl) 2010-04-30
AU2007236003B2 (en) 2012-10-18
WO2007115975A3 (de) 2008-02-14
DE502007002185D1 (de) 2010-01-14
ES2337622T3 (es) 2010-04-27
CA2646899A1 (en) 2007-10-18
RS51211B (sr) 2010-12-31
AU2007236003A1 (en) 2007-10-18
JP5128578B2 (ja) 2013-01-23
EP2001456B1 (de) 2009-12-02
PT2001456E (pt) 2010-03-03
WO2007115975A2 (de) 2007-10-18
PL2001456T3 (pl) 2010-05-31
EA200802104A1 (ru) 2009-04-28

Similar Documents

Publication Publication Date Title
HRP20100113T1 (hr) Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja
UA94052C2 (uk) Похідні піридазину
MX346879B (es) Formulaciones de ketorolaco listas para su uso.
MA32692B1 (fr) Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin
AU2018236805B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
MY151295A (en) Pyrimidyl indoline compound
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
WO2006077025A3 (en) Morpholines as 5ht2c agonists
EP4293009A3 (en) Fenfluramine compositions and methods of preparing the same
WO2011017201A3 (en) Dp2 antagonist and uses thereof
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
TW200740764A (en) Pyrazolone derivatives
GEP20115222B (en) New pharmaceutical compounds
WO2009140341A3 (en) Atorvastatin compositions
WO2011025982A3 (en) Tetracycline compounds
TN2011000307A1 (en) Galenic formulation of organic compounds
MY163762A (en) Therapeutic agent for chronic renal failure
TW200800984A (en) New compounds
HK1131984A1 (en) Substituted carboxamides as group i metabotropic receptor antagonists
MY148393A (en) Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
MX2012007927A (es) Antagonistas de dp2 y usos del mismo.
JP2009532434A5 (hr)